John Byrd

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. pmc The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo
    David M Lucas
    Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA
    PLoS ONE 5:e10941. 2010
  2. pmc Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease
    Erin Hertlein
    Department of Internal Medicine, Division of Hematology, Comprehensive Cancer Center at The Ohio State University, Columbus, Ohio, United States of America
    PLoS ONE 8:e76607. 2013
  3. pmc Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia
    Houda Alachkar
    Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, USA
    J Hematol Oncol 6:21. 2013
  4. pmc Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
    John C Byrd
    Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, OH 43210, USA
    N Engl J Med 369:32-42. 2013
  5. pmc Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies
    Jennifer A Woyach
    Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 31:440-7. 2013
  6. pmc Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia
    John C Byrd
    The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
    Leuk Lymphoma 53:2136-42. 2012
  7. pmc Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia
    Rainer Claus
    German Cancer Research Center, Heidelberg, Germany
    J Clin Oncol 30:2483-91. 2012
  8. pmc Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach
    Deborah M Stephens
    Division of Hematology, Department of Internal Medicine and Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Haematologica 97:423-7. 2012
  9. ncbi request reprint Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia
    John C Byrd
    The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA
    Clin Cancer Res 13:4448-55. 2007
  10. ncbi request reprint Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901
    John C Byrd
    The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Leuk Lymphoma 50:1589-96. 2009

Research Grants

Detail Information

Publications107 found, 100 shown here

  1. pmc The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo
    David M Lucas
    Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA
    PLoS ONE 5:e10941. 2010
    ..We therefore investigated the novel DAC inhibitor AR-42 to determine its efficacy in B-cell malignancies...
  2. pmc Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease
    Erin Hertlein
    Department of Internal Medicine, Division of Hematology, Comprehensive Cancer Center at The Ohio State University, Columbus, Ohio, United States of America
    PLoS ONE 8:e76607. 2013
    ..These studies describe a new CLL cell line that extends currently available models to study gene function in this disease. ..
  3. pmc Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia
    Houda Alachkar
    Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, USA
    J Hematol Oncol 6:21. 2013
    ..We examined here the preclinical activity of silvestrol in FLT3-ITD and FLT3 wild-type (wt) AML...
  4. pmc Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
    John C Byrd
    Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, OH 43210, USA
    N Engl J Med 369:32-42. 2013
    ..Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation of CLL cells...
  5. pmc Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies
    Jennifer A Woyach
    Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 31:440-7. 2013
    ..Chronic lymphocytic leukemia (CLL) is a disease of the elderly, yet few clinical trials include a significant number of older patients, and outcomes after specific therapies can be different depending on age...
  6. pmc Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia
    John C Byrd
    The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
    Leuk Lymphoma 53:2136-42. 2012
    ..0 mg/kg, but demonstrated minimal single-agent activity. Future efforts with lucatumumab in CLL should focus on combination-based therapy...
  7. pmc Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia
    Rainer Claus
    German Cancer Research Center, Heidelberg, Germany
    J Clin Oncol 30:2483-91. 2012
    ..We therefore used comprehensive DNA methylation profiling of the ZAP-70 regulatory region to identify sites important for transcriptional control...
  8. pmc Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach
    Deborah M Stephens
    Division of Hematology, Department of Internal Medicine and Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Haematologica 97:423-7. 2012
    ..Development of treatment approaches including flavopiridol should be considered for these older patients...
  9. ncbi request reprint Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia
    John C Byrd
    The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA
    Clin Cancer Res 13:4448-55. 2007
    ..We conducted a phase 1, dose escalation and schedule optimization study of the primatized anti-CD23 antibody, lumiliximab, in patients with previously treated and refractory CLL...
  10. ncbi request reprint Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901
    John C Byrd
    The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Leuk Lymphoma 50:1589-96. 2009
    ..The administration of alemtuzumab as consolidation therapy following an abbreviated fludarabine induction is feasible but requires close monitoring for CMV infection and other infectious events...
  11. pmc Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia
    John C Byrd
    The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
    Blood 115:489-95. 2010
    ..A randomized trial comparing lumiliximab plus FCR with FCR alone is underway to define the benefit of this combination in relapsed CLL. This trial was registered at clinicaltrials.gov as NCT00103558...
  12. ncbi request reprint Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy
    John C Byrd
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 24:437-43. 2006
    ..1), and p53 mutations. To date, the impact of these same prognostic factors have not been examined relative to treatment outcome with chemoimmunotherapy...
  13. pmc Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
    John C Byrd
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    Blood 109:399-404. 2007
    ..Patients with bulky disease and high-risk genetic features have achieved durable responses, thereby justifying further study of flavopiridol in CLL and other diseases...
  14. pmc Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease
    Thomas S Lin
    Division of Hematology and Oncology, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 27:6012-8. 2009
    ..Given the relevance of these findings to treating genetically high-risk CLL, a prospective confirmatory study was initiated...
  15. pmc Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101
    Thomas S Lin
    The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 28:4500-6. 2010
    ..To determine if alemtuzumab consolidation improves response rate and progression-free survival (PFS) after induction chemoimmunotherapy in previously untreated symptomatic patients with chronic lymphocytic leukemia...
  16. doi request reprint A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents
    Rosa Lapalombella
    Division of Hematology Oncology, Department of Internal Medicine, Ohio State University, Columbus, OH 43210, USA
    Clin Cancer Res 14:569-78. 2008
    ..We describe generation and utilization of cell lines that stably express CD52 both in vitro and in vivo...
  17. pmc 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition
    Erin Hertlein
    Department of Internal Medicine, Division of Hematology and Oncology, Comprehensive Cancer Center at The Ohio State University, 410West 12th Avenue, Columbus, OH 43210, USA
    Blood 116:45-53. 2010
    ..Therefore, the effect of 17-DMAG on NF-kappaB signaling pathways represents a novel therapy warranting further clinical pursuit in this and other B-cell lymphoproliferative disorders...
  18. ncbi request reprint Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
    John C Byrd
    Division of Hematology and Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus 43210 1240, USA
    Blood 100:4325-36. 2002
    ....
  19. ncbi request reprint Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805
    John C Byrd
    Division of Hematology Oncology, Department of Medicine, The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 11:4176-81. 2005
    ..We sought to determine if flavopiridol has activity in previously treated CLL using two schedules of administration...
  20. pmc Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma
    Lapo Alinari
    Department of Internal Medicine, Division of Hematology and Oncology, Ohio State University, Columbus, Ohio 43210, USA
    MAbs 1:31-40. 2009
    ....
  21. ncbi request reprint Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity
    Guido Marcucci
    Division of Hematology Oncology, The Comprehensive Cancer Center, The Ohio State University, 433A Starling Loving Hall, 320 West 10th Ave, Columbus, OH 43210, USA
    J Clin Oncol 23:3404-11. 2005
    ..Herein, we investigated the feasibility of this approach in untreated elderly AML patients by administering oblimersen sodium (G3139), an 18-mer phosphorothioate antisense to Bcl-2, during induction and consolidation treatments...
  22. pmc Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders
    Thomas S Lin
    Division of Hematology and Oncology, The Ohio State University, Center for Biostatistics, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 28:418-23. 2010
    ..We conducted a phase I study of flavopiridol, fludarabine, and rituximab (FFR) in patients with mantle-cell lymphoma (MCL), indolent B-cell non-Hodgkin's lymphomas (B-NHL), and CLL to determine the activity of FFR...
  23. ncbi request reprint Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia
    Shujun Liu
    Divisions of Hematology Oncology, Department of Internal Medicine and the Comprehensive Cancer Center, Ohio State University, Columbus, Ohio, USA
    Cancer Res 65:1277-84. 2005
    ..These results suggest a novel mechanism for gene silencing mediated by RUNX1/MTG8 and support the combination of HDAC and DNMT inhibitors as a novel therapeutic approach for t(8;21) AML...
  24. ncbi request reprint Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity
    Syed Rehan A Hussain
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA
    Clin Cancer Res 13:2144-50. 2007
    ..Mcl-1 has also been reported to mediate resistance to rituximab in CLL. We therefore investigated whether direct reduction of Mcl-1 was sufficient to induce apoptosis and increase sensitivity to rituximab...
  25. pmc Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia
    Amy J Johnson
    Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    Blood 108:1334-8. 2006
    ....
  26. ncbi request reprint Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461
    John C Byrd
    Division of Hematology and Oncology and the Comprehensive Cancer Center, The Ohio State University, B302A Starling Loving Hall, 320 W 10th Ave, Columbus, OH 43210 1240, USA
    J Clin Oncol 22:1087-94. 2004
    ..To study the impact of repetitive (three to four courses) versus a single course of high-dose cytarabine (HDAC) consolidation therapy on outcome of patients with acute myeloid leukemia (AML) and inv(16)(p13q22) or t(16;16)(p13;q22)...
  27. pmc Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
    Neil E Kay
    Mayo Clinic, Stabile 628, 200 First St SW, Rochester, MN 55905, and The Ohio State University, Columbus, USA
    Blood 109:405-11. 2007
    ....
  28. pmc Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method
    Zhongfa Liu
    College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA
    Nucleic Acids Res 35:e31. 2007
    ..Our data support the use of our LC-MS/MS method for clinical pharmacodynamic determination of changes in GDM in vivo...
  29. pmc Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia
    Tasneem Motiwala
    Department of Molecular and Cellular Biochemistry, Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 13:3174-81. 2007
    ....
  30. ncbi request reprint Rituximab in chronic lymphocytic leukemia
    Samantha M Jaglowski
    Division of Hematology Oncology, Department of Medicine, The Ohio State University, Columbus, OH
    Semin Hematol 47:156-69. 2010
    ..Future efforts focusing on novel combination-based strategies will be required to fully appreciate the benefit of this therapy in CLL...
  31. pmc MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1
    Ramiro Garzon
    Department of Medicine, Ohio State University, Columbus, 43210, USA
    Blood 113:6411-8. 2009
    ....
  32. pmc Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia
    Andrew Mone
    Division of Hematology Oncology, Department of Internal Medicine, The Comprehensive Cancer Center, The Ohio State University, Columbus, 43210, USA
    Blood 106:3380-2. 2005
    ..The unprecedented response and the profound suppression of HTLV-1 viral load observed in this patient suggest that further clinical investigation of alemtuzumab in ATL is warranted...
  33. ncbi request reprint Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance
    Rajat Bannerji
    Division of Hematology Oncology, Starling Loving Hall, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 21:1466-71. 2003
    ..Here we examine pretreatment biologic features that promote resistance to apoptosis and CDC in CLL patients and correlate it with clinical outcome to rituximab-based therapy...
  34. pmc Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance
    Ping Hui Tseng
    Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, 336 L M Parks Hall, Columbus, OH 43210, USA
    Blood 105:4021-7. 2005
    ..This synergistic action was, at least in part, mediated through the concerted effect on phospho-Akt. Together these data provide a novel therapeutic strategy to overcome imatinib mesylate resistance, especially with the Abl mutant T315I...
  35. ncbi request reprint FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma
    Qing Liu
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 16:3182-92. 2010
    ..Because of the absence of curative therapy for MCL, we explored FTY720 as a novel agent against MCL...
  36. ncbi request reprint Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro
    Sabyasachi Biswas
    Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    Leuk Res 34:925-31. 2010
    ..Furthermore, Hu1D10-mediated cell death was enhanced with ATO and ascorbic acid, thus justifying potential combination of ATO/arsenic trioxide therapy with antibodies such as Hu1D10 that also cause accumulation of ROS...
  37. pmc Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells
    Rosa Lapalombella
    Division of Hematology Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, USA
    Blood 112:5180-9. 2008
    ..In addition, they suggest that lenalidomide therapy might be useful to enhance targeted delivery of RNAi-based therapies using CD20 immunoliposomes in B-cell malignancies...
  38. pmc Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia
    Rebekah L Browning
    Ohio State University, Columbus, OH, United States
    Leuk Res 31:1737-40. 2007
    ..199) were noted with lower TCL-1 expression. These data suggest TCL-1 expression may help predict treatment outcome in CLL patients following chemoimmunotherapy, and examination in larger studies is warranted...
  39. pmc Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical
    Xiaobin Zhao
    Division of Hematology Oncology, Department of Medicine, College of Medicine, The Ohio State University, Columbus, OH 43210, USA
    Blood 110:2569-77. 2007
    ..These findings provide strong justification for CD37 as a therapeutic target and introduce small modular immunopharmaceuticals as a novel class of targeted therapies for B-cell malignancies...
  40. ncbi request reprint Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia
    Guido Marcucci
    Division of Hematology Oncology, Department of Medicine, and the Comprehensive Cancer Center, Ohio State University, Columbus 43210, USA
    Blood 101:425-32. 2003
    ..The encouraging clinical and laboratory results justify the current plans for a phase 3 study in previously untreated high-risk AML (ie, age at least 60 years)...
  41. pmc The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
    Don M Benson
    Division of Hematology Oncology, The Ohio State University Medical Center, Columbus, OH, USA
    Blood 116:2286-94. 2010
    ..A phase 2 clinical trial of CT-011 in combination with lenalidomide for patients with MM should be considered...
  42. ncbi request reprint Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells
    Andrew P Mone
    Division of Hematology Oncology, The Ohio State University, Columbus 43210, USA
    Blood 103:1846-54. 2004
    ..These data suggest that Hu1D10 ligation in CLL cells induces death and survival signals for which combination therapies may be designed to greatly enhance efficiency of both Hu1D10 and other class II antibodies in development...
  43. ncbi request reprint Flavopiridol in the treatment of chronic lymphocytic leukemia
    Beth A Christian
    Division of Hematology and Oncology, Ohio State University, Columbus, Ohio 43210, USA
    Curr Opin Oncol 19:573-8. 2007
    ..This review focuses on a novel dosing regimen that has achieved significant clinical activity in relapsed, poor-risk chronic lymphocytic leukemia...
  44. pmc Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma
    Sharmistha Pal
    Department of Molecular and Cellular Biochemistry, The Ohio State University, Columbus, OH 43210, USA
    EMBO J 26:3558-69. 2007
    ..Thus, our studies indicate that aberrant expression of PRMT5 leads to altered epigenetic modification of chromatin, which in turn impacts transcriptional performance of anti-cancer genes and growth of transformed lymphoid cells...
  45. ncbi request reprint TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia
    Aparna Raval
    Division of Human Cancer Genetics, Department of Medicine, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 23:3877-85. 2005
    ..Herein we report selective epigenetic silencing of the transcription factor TWIST2 (DERMO1) in Ig V(H) mutated CLL and describe a semiquantitative assay to study promoter methylation of this gene in primary tumor cells...
  46. pmc Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy
    Jonathan P Butchar
    Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA
    Clin Cancer Res 16:2065-75. 2010
    ..Here, we wished to test the effect of TLR7/8 activation on monocyte Fcgamma receptor (FcgammaR) function, as they are critical mediators of antibody therapy...
  47. ncbi request reprint Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia
    Guowei Dai
    Division of Pharmaceutics, College of Medicine and Public Health, Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 11:2998-3008. 2005
    ..This study aimed to assess whether detectable intracellular concentrations of G3139 are achievable in vivo and how these relate to Bcl-2 down-regulation...
  48. pmc Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma
    Kristie A Blum
    Division of Hematology Oncology, Department of Internal Medicine, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Leuk Lymphoma 50:349-56. 2009
    ..Clofarabine exhibits evidence of single agent activity in relapsed or refractory DLBCL. However, further study with novel administration schedules that maintain this efficacy and limit toxicity is warranted...
  49. pmc CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody
    Farrukh T Awan
    Division of Hematology Oncology, Department of Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA
    Blood 115:1204-13. 2010
    ..These findings provide strong support for further clinical development of XmAb5574 as both a monotherapy and in combination with lenalidomide for the therapy of CLL and related CD19(+) B-cell malignancies...
  50. ncbi request reprint Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria
    Kristie A Blum
    The Ohio State University, Division of Hematology Oncology, Starling Loving Hall, Room B324, Columbus, OH 43210, USA
    J Clin Oncol 25:5624-9. 2007
    ..The widespread use of computed tomography (CT) scans has prompted many to advocate for the incorporation of this test into CLL response criteria...
  51. pmc The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo
    David M Lucas
    Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
    Blood 113:4656-66. 2009
    ..These data indicate silvestrol has efficacy against B cells in vitro and in vivo and identify translational inhibition as a potential therapeutic target in B-cell leukemias...
  52. pmc Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab
    Farrukh T Awan
    The Ohio State University, Columbus, USA
    Blood 113:535-7. 2009
    ..Because the trials described were conducted before the requirement to register them was implemented, they are not registered in a clinical trial database.)...
  53. ncbi request reprint Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)
    John C Byrd
    Division of Hematology Oncology, Department of Medicine, The Ohio State University, Columbus, USA
    Blood 101:6-14. 2003
    ..Rituximab administered concurrently with fludarabine in previously untreated CLL patients demonstrates marked clinical efficacy and acceptable toxicity. Phase 3 studies using this combination approach for patients with CLL are warranted...
  54. pmc Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia
    Mitch A Phelps
    Comprehensive Cancer Center, College of Pharmacy, Division of Pharmaceutics, The Ohio State University, Columbus, OH 43210, USA
    Blood 113:2637-45. 2009
    ..These composite results confirm high activity of this pharmacokinetically derived schedule in relapsed, genetically high-risk CLL. Furthermore, PK describes some, but not all, variability in response and toxicity...
  55. pmc Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies
    Mehdi Hamadani
    Division of Hematology Oncology, Blood and Marrow Transplantation Section, and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Biol Blood Marrow Transplant 15:1422-30. 2009
    ....
  56. pmc A novel liposomal formulation of flavopiridol
    Xiaojuan Yang
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
    Int J Pharm 365:170-4. 2009
    ..Further preclinical studies are warranted to define the toxicity and therapeutic efficacy of this novel formulation...
  57. ncbi request reprint Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia
    Michael R Grever
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
    Best Pract Res Clin Haematol 20:545-56. 2007
    ..1) is a major focus of several investigators. Selection of therapy based on high-risk genomic features represents an appropriate treatment approach supported by currently available published data...
  58. pmc Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia
    Kristie A Blum
    Division of Hematology Oncology, Ohio State University Medical Center, Columbus, OH 43210, USA
    Br J Haematol 147:507-14. 2009
    ..Future investigations in CLL should focus on broad HDAC inhibition, combination strategies, and approaches to diminish constitutional symptoms associated with this class of drugs...
  59. doi request reprint Flavopiridol in chronic lymphocytic leukemia: a concise review
    Beth A Christian
    Division of Hematology Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Clin Lymphoma Myeloma 9:S179-85. 2009
    ..Several other investigational CDKi in preclinical and early clinical development are briefly discussed in this review...
  60. ncbi request reprint Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia
    Amy J Johnson
    Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA
    Br J Haematol 139:837-44. 2007
    ..Furthermore, our data indicates that AKT and Hsp70 protein levels are relevant pharmacodynamic endpoints to monitor the in vivo effect of 17-AAG therapy...
  61. ncbi request reprint Rituximab in B-cell chronic lymphocytic leukemia
    Thomas S Lin
    The Ohio State University, The Arthur James Comprehensive Cancer Center, Columbus, OH, USA
    Semin Oncol 30:483-92. 2003
    ..However, such infusion toxicity is minimized with appropriate premedication and a stepped up dosing schedule, allowing safe and effective use of rituximab in this disease...
  62. pmc Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia
    Shujun Liu
    Division of Hematology Oncology, The Ohio State University, Columbus, OH 43210, USA
    Cancer Cell 17:333-47. 2010
    ....
  63. pmc Accurate quantification of DNA methylation using combined bisulfite restriction analysis coupled with the Agilent 2100 Bioanalyzer platform
    Romulo Martin Brena
    Department of Molecular Genetics, The Ohio State University, Columbus, OH, USA
    Nucleic Acids Res 34:e17. 2006
    ....
  64. pmc Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias
    William Blum
    Division of Hematology and Oncology and the Comprehensive Cancer Center, Department of Medicine, The Ohio State University, B310 Starling Loving Hall, 320 West 10 Avenue, Columbus, OH 43210, USA
    Haematologica 95:1098-105. 2010
    ....
  65. ncbi request reprint Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011
    John C Byrd
    Division of Hematology Oncology, Department of Medicine, The Ohio State University, Columbus, OH 43210, USA
    Blood 105:49-53. 2005
    ..Confirmation of these findings will require a prospective randomized trial comparing fludarabine and rituximab to fludarabine...
  66. pmc Second malignancies in B-cell chronic lymphocytic leukaemia: possible association with human papilloma virus
    Joseph M Flynn
    Division of Haematology and Oncology, The Ohio State University Medical Center, Columbus, OH 43210, USA
    Br J Haematol 149:388-90. 2010
    ..None of control samples were HPV-positive, while 53% of samples from the CLL group were positive. This report describes preliminary evidence for the presence of HPV in secondary malignancies, in patients with CLL...
  67. ncbi request reprint The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction
    John C Byrd
    Division of Hematology Oncology, The Ohio State University, B302 Starling Loving Hall, 320 W 10th Ave, Columbus, OH 43210, USA
    Blood 99:1038-43. 2002
    ....
  68. ncbi request reprint Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality
    Naeem A Ali
    Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Ohio State University, Columbus, Ohio 43210, USA
    Cancer 110:96-102. 2007
    ..The authors hypothesized that hyperglycemia may be associated with adverse outcomes in patients with acute myeloid leukemia (AML) and sought to determine whether this association exists in this population...
  69. ncbi request reprint Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia
    William Blum
    Department of Medicine, Division of Hematology and Oncology, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 25:3884-91. 2007
    ..To determine an optimal biologic dose (OBD) of decitabine as a single agent and then the maximum-tolerated dose (MTD) of valproic acid (VA) combined with decitabine in acute myeloid leukemia (AML)...
  70. ncbi request reprint Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors
    Qiang Lu
    Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA
    J Med Chem 47:467-74. 2004
    ....
  71. ncbi request reprint Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions
    Gerard Lozanski
    Department of Pathology, Ohio State University, Columbus, OH 43210, USA
    Blood 103:3278-81. 2004
    ..The median response duration for this subset of patients was 8 months (range, 3-17 months). These data suggest that alemtuzumab may be an effective therapy for patients with CLL with p53 mutations or deletions...
  72. pmc Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study
    Nyla A Heerema
    The Ohio State University, 1645 Neil Ave, 129 Hamilton Hall, Columbus, OH 43210, USA
    Cancer Genet Cytogenet 203:134-40. 2010
    ..Because karyotypic complexity is prognostic and is not detectable by standard FISH analyses, stimulation with CpG-ODN is useful for identifying this additional prognostic factor in CLL...
  73. ncbi request reprint Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia
    Warren Fiskus
    Authors Affiliations Houston Methodist Research Institute The University of Texas M D Anderson Cancer Center, Houston, Texas Hematology Branch, National Heart Lung and Blood Institute NHLBI National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland The University of Kansas Medical Center Institute for Advancing Medical Innovation, Kansas University, Kansas City, Kansas Division of Hematology, Department of Internal Medicine, The Comprehensive Cancer Center at The Ohio State University, Columbus, Ohio and Weill Cornell Medical College, New York, New York
    Cancer Res 74:2520-32. 2014
    ..Our results provide a rationale to reposition the approved drug auranofin for clinical evaluation in the therapy of CLL...
  74. ncbi request reprint Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines
    Jim J Xiao
    College of Pharmacy, The Ohio State University, Columbus, OH, USA
    J Pharmacol Exp Ther 314:467-75. 2005
    ..This study reveals a significant role of histone acetylation in MDR1 transcription, which seems to mediate FK228 resistance...
  75. pmc Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712
    Jennifer A Woyach
    The Ohio State University, 320 West 10 Ave, Columbus, OH 43210, USA
    J Clin Oncol 29:1349-55. 2011
    ..The long-term follow-up of these regimens with respect to progression, survival, risk of secondary leukemia, and impact of genomic risk factors has been limited...
  76. ncbi request reprint Rituximab: converging mechanisms of action in non-Hodgkin's lymphoma?
    Charles F Eisenbeis
    Clin Cancer Res 9:5810-2. 2003
  77. ncbi request reprint Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population
    Jeremy G Perkins
    Department of Medicine, Walter Reed Army Medical Center, Washington, D C, USA
    Cancer 94:2033-9. 2002
    ..Little data exist regarding the frequency of infections in this population treated with noninvestigational best supportive care therapies...
  78. ncbi request reprint High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation
    William Blum
    Division of Hematology and Oncology and Comprehensive Cancer Center, The Ohio State University Hospitals, Columbus, Ohio 43210, USA
    Biol Blood Marrow Transplant 12:61-7. 2006
    ....
  79. ncbi request reprint Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity
    Ian W Flinn
    Department of Oncology, John Hopkins University, Baltimore, MD, USA
    Leuk Res 29:1253-7. 2005
    ..Based upon this pre-clinical data, a phase I/II study of 24h flavopiridol was performed...
  80. ncbi request reprint Pentostatin in steroid-refractory acute graft-versus-host disease
    Javier BolaƱos-Meade
    Division of Hematologic Malignancies, Department of Oncology, Johns Hopkins Univeristy, Baltimore, MD 21231, USA
    J Clin Oncol 23:2661-8. 2005
    ..In steroid-refractory aGVHD, mortality is very high. Pentostatin, a potent inhibitor of adenosine deaminase, induces lymphocyte apoptosis and may be useful in the treatment of this condition...
  81. ncbi request reprint Changing the way we think about chronic lymphocytic leukemia
    Thomas S Lin
    J Clin Oncol 23:4009-12. 2005
  82. ncbi request reprint Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study
    Charles F Eisenbeis
    Division of Hematology Oncology, Comprehensive Cancer Center, and Center for Biostatistics, The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 10:6101-10. 2004
    ..We also conducted a phase I trial of IL-2 and rituximab in relapsed B-NHL to study whether expansion of natural killer (NK) cells and enhanced cellular cytotoxicity could be safely accomplished in vivo...
  83. ncbi request reprint ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia
    Laura Z Rassenti
    Chronic Lymphocytic Leukemia Research Consortium, University of California, San Diego, La Jolla 92093, USA
    N Engl J Med 351:893-901. 2004
    ....
  84. ncbi request reprint Antibody therapy for chronic lymphocytic leukemia: a promising new modality
    Thomas S Lin
    Division of Hematology and Oncology, Starling Loving Hall, Room 302, The Arthur James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Hematol Oncol Clin North Am 18:895-913, ix-x. 2004
    ..Future efforts in developing combination strategies with rituximab, alemtuzumab, and potentially other new antibodies offer great promise for the future treatment of CLL...
  85. ncbi request reprint FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia
    Thomas S Lin
    Department of Medicine, Division of Hematology Oncology, The Ohio State University, Columbus 43210, USA
    Blood 105:289-91. 2005
    ..Future studies examining larger cohorts of alemtuzumab-treated patients with CLL will be required to definitively determine the predictive value of specific FCGR polymorphisms to treatment response...
  86. ncbi request reprint Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia
    Michael Keating
    M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma 4:220-7. 2004
    ..Because high response rates and few complications are observed in previously untreated patients, the use of alemtuzumab earlier in therapy may provide optimum benefit to patients...
  87. ncbi request reprint Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia
    Sherif S Farag
    Division of Hematology Oncology and the Department of Biostatistics, The Ohio State University, Columbus, OH 43210, USA
    Blood 103:1472-4. 2004
    ..These data suggest that Fc gamma RIIIa polymorphisms are not predictive of response in CLL and that, unlike the case with FL, mechanisms of tumor clearance other than antibody-dependent cellular cytotoxicity may be more important...
  88. ncbi request reprint Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
    Donna Weber
    University of Texas, M D Anderson Cancer Center, Houston, TX, USA
    Semin Oncol 30:127-31. 2003
    ....
  89. ncbi request reprint Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab
    John C Byrd
    The Division of Hematology Oncology, Ohio State University, Columbus, Ohio 43210, USA
    Cancer Res 63:36-8. 2003
    ..These data suggest that interphase cytogenetics in CLL may be predictive of a response to rituximab therapy and provide support for additional studies validating risk-adapted therapy in this disease...
  90. ncbi request reprint Acute myeloid leukemia clinical practice guidelines in oncology
    Margaret R O'Donnell
    City of Hope Cancer Center, Los Angeles, CA, USA
    J Natl Compr Canc Netw 4:16-36. 2006
  91. ncbi request reprint CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia
    Te Hui Liu
    Department of Molecular Virology, Immunology, and Medical Genetics, Division of Human Cancer Genetics, The Ohio State University, 420 West 12th Avenue, Columbus, OH 43210, USA
    Cancer Res 66:653-8. 2006
    ..Our results suggest that silencing of SFRPs by CpG island methylation is one possible mechanism contributing to aberrant activation of Wnt signaling pathway in CLL...
  92. ncbi request reprint Non-Hodgkin's lymphomas
    Andrew D Zelenetz
    J Natl Compr Canc Netw 6:356-421. 2008
  93. doi request reprint Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia
    Leslie A Andritsos
    Division of Hematology Oncology, Department of Medicine, The Ohio State University, Columbus, OH, USA
    J Clin Oncol 26:2519-25. 2008
    ..Herein, we highlight life-threatening tumor flare when higher doses of lenalidomide are administered to patients with CLL and provide a potential mechanism for its occurrence...
  94. pmc IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro
    Aruna Gowda
    Division of Hematology Oncology, Department of Medicine, The Ohio State University, Columbus, USA
    Blood 111:4723-30. 2008
    ....
  95. pmc Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia
    Shujun Liu
    Division of Hematology Oncology, The Ohio State University, Columbus, OH 43210, USA
    Blood 111:2364-73. 2008
    ..Our results unveil the Sp1/NF-kappaB pathway as a modulator of DNA methyltransferase activity in human cancer and identify bortezomib as a novel epigenetic-targeting drug...
  96. ncbi request reprint Have we forgotten the purpose of phase III studies?
    Joseph M Flynn
    J Clin Oncol 25:5553-5. 2007
  97. ncbi request reprint A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma
    Carl R Willis
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Ann Hematol 85:301-7. 2006
    ..5 months for nonresponders. The combination of pentostatin, chlorambucil, and theophylline is the active regimen in patients with FL and B-cell CLL...
  98. ncbi request reprint Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia
    Stefan Faderl
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 107:916-24. 2006
    ..In view of the evidence for its activity, further exploration of bortezomib in combination with other agents is warranted...
  99. ncbi request reprint Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153
    Kristie A Blum
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio 43210, USA
    Cancer 107:2817-25. 2006
    ..The objective of this study was to determine the efficacy and toxicity of 2-chlorodeoxyadenosine (2-CdA) in patients with untreated, indolent non-Hodgkin lymphoma (NHL)...
  100. ncbi request reprint A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma
    Khuda D Khan
    American Health Network Oncology Hematology, Indianapolis, Indiana, USA
    Clin Cancer Res 12:7046-53. 2006
    ..Therefore, a large, multicenter phase 2 trial to assess the effects of rIL-2 on rituximab therapy in patients with rituxumab-refractory low-grade NHL was conducted...
  101. ncbi request reprint Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997
    Michael R Grever
    Eastern Cooperative Oncology Group, Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
    J Clin Oncol 25:799-804. 2007
    ..1), and p53 mutations have been reported to predict the clinical course and overall survival of patients with chronic lymphocytic leukemia (CLL). In addition, ZAP-70 and Bcl-2 family proteins have been explored as predictors of outcome...

Research Grants4

  1. Hu1D10 in CLL: CLINICAL AND LABORATORY STUDIES
    John Byrd; Fiscal Year: 2003
    ..abstract_text> ..
  2. Hu1D10 in CLL: CLINICAL AND LABORATORY STUDIES
    John Byrd; Fiscal Year: 2004
    ..abstract_text> ..
  3. Hu1D10 in CLL: CLINICAL AND LABORATORY STUDIES
    John Byrd; Fiscal Year: 2005
    ..abstract_text> ..
  4. Hu1D10 in CLL: CLINICAL AND LABORATORY STUDIES
    John Byrd; Fiscal Year: 2006
    ..abstract_text> ..